Content deleted Content added
M97uzivatel (talk | contribs) No edit summary |
M97uzivatel (talk | contribs) |
||
Line 21:
In virtually every case, competitive inhibitors bind in the same [[binding site]] (active site) as the substrate, but same-site binding is not a requirement. A competitive inhibitor could bind to an [[allosteric]] site of the free enzyme and prevent substrate binding, as long as it does not bind to the allosteric site when the substrate is bound. For example, [[strychnine]] acts as an allosteric inhibitor of the glycine receptor in the mammalian spinal cord and brain stem. Glycine is a major post-synaptic inhibitory neurotransmitter with a specific receptor site. Strychnine binds to an alternate site that reduces the affinity of the glycine receptor for glycine, resulting in convulsions due to lessened inhibition by the glycine.<ref>{{cite book |title= Pharmacology for Nurse Anesthesiology |veditors= Ouellette R, Joyce JA |year= 2011 |publisher= Jones & Bartlett Learning |isbn= 978-0-7637-8607-6 |chapter= Chapter 2. Pharmacodynamics: The Study of Drug Action | vauthors = Dick RM |url-access= registration |url= https://archive.org/details/pharmacologyforn0000ouel }}</ref>
In competitive inhibition, the maximum velocity (<math>V_\max</math>) of the reaction is unchanged, while the apparent affinity of the substrate to the binding site is decreased (the <math>K_d</math> dissociation constant is apparently increased). The change in <math>K_m</math> ([[Michaelis–Menten
[[File:Allosteric comp inhib 1.svg|350px|Competitive inhibition can also be allosteric, as long as the inhibitor and the substrate cannot bind the enzyme at the same time.|thumb]]
|